Treatment with AMX0035 significantly extended the median survival of amyotrophic lateral sclerosis (ALS) patients by more than 10 months compared…
Articles by Marisa Wexler, MS
WVE-004, Wave Life Sciences‘ experimental therapy for people with amyotrophic lateral sclerosis (ALS) associated with mutations in the C9ORF72…
Treatment with Coya Therapeutics‘ ALS001, a regulatory T-cell (Treg) therapy being developed for amyotrophic lateral sclerosis (ALS), was found…
“Clustering” people with amyotrophic lateral sclerosis (ALS) based on biological data could be useful for identifying those most likely…
The experimental therapy WVE-004 appears to be engaging its intended target and reducing the amount of toxic proteins in people…
A CRISPR-based gene editing system could be used to reduce the activity of genes associated with amyotrophic lateral sclerosis…
A novel system that involves electrodes implanted in the brain allowed a 34-year-old man with amyotrophic lateral sclerosis (ALS)…
Two independent teams of scientists have unraveled the molecular mechanism by which abnormal localization of the TDP-43 protein, which is…
Treatment with the cell therapy NurOwn may slow the progression of amyotrophic lateral sclerosis (ALS) for those with…
Treatment with Clene Nanomedicine’s experimental medicine CNM-Au8 may decrease the risk of disease progression or death in people with…